GOSS:NASDAQ, Gossamer Bio, Inc.

GOSS stock overview

Gossamer Bio, Inc. (GOSS:NASDAQ) closed at $9.15 on October 26, 2026, down 4.74% on the day. The stock trades 97.0% below its 52-week high of $309.60 and 10.4% above its 52-week low of $8.29. Gossamer Bio, Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price: $9.15
Day change: -4.74%
Volume: 250,631
Average volume: 373,683
Market cap: 55M+
52-week range: $8.29 – $309.60
50-day average: $11.45
200-day average: $46.01

Price action over the past year

In 251 trading sessions since October 24, 2025, GOSS closed higher on 114 days (45%). Its best day was July 27, 2026 (+46.32%) and its worst was February 23, 2026 (-80.14%). The stock moved 10% or more in a single session 28 times. It opened at least 5% above the previous day's high 4 times.

Recent signals

Oct 1, 2026: News catalyst: Split (News Catalysts scanner)
Aug 26, 2026: Dropped 15.1% in a single session (Dips & Crashes scanner)

GOSS news

Oct 17, 2026: Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib Risks
Oct 13, 2026: Adobe downgraded, VF Corp. upgraded: Wall Street's top analyst calls
Oct 1, 2026: Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA
Sep 23, 2026: Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Sep 16, 2026: Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Sep 11, 2026: Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Sep 9, 2026: Gossamer Bio Announces 1-for-80 Reverse Stock Split
Sep 8, 2026: Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio

About Gossamer Bio, Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its pipeline products include GB001 (DP2 Antagonist), GB002 (PDGF Receptor Kinase Inhibitor), GB004 (HIF-1a Stabilizer), and others.

Similar stocks

Find more stocks like GOSS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.